Radius Health Inc. announced that it has strengthened its management team with the addition of John Yates, M.D. as Chief Medical Officer and Greg Williams, Ph.D. as Chief Development Officer and the promotion of Gary Hattersley, Ph.D. to Chief Scientific Officer. Prior to joining Radius, Dr. Yates was President of Global Research and Development for Takeda Pharmaceuticals, where he led the successful NDA filings of two new chemical entities and strengthened the development pipeline across multiple therapeutic areas. Prior to joining Radius, Dr. Williams was Vice President of Regulatory Affairs, Global Product and Clinical Development, and Program Management with The Medicines Company, where he led the successful NDA and MAA filings of the IV antihypertensive drug Cleviprex(R).

Gary Hattersley, Ph.D., previously served as Senior Vice President, Preclinical Development at Radius. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals, with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases.